CN113425726A - Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor - Google Patents

Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor Download PDF

Info

Publication number
CN113425726A
CN113425726A CN202110626296.8A CN202110626296A CN113425726A CN 113425726 A CN113425726 A CN 113425726A CN 202110626296 A CN202110626296 A CN 202110626296A CN 113425726 A CN113425726 A CN 113425726A
Authority
CN
China
Prior art keywords
beta
lactamase
containing compound
methyl
pyrazinylethylthiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110626296.8A
Other languages
Chinese (zh)
Other versions
CN113425726B (en
Inventor
石磊
何羡霞
张冰
姜志辉
杨琰
袁进
蔡敏捷
蔡学究
李小荣
廖扬
许文平
黄雪峰
陈龙浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Theater Command General Hospital of PLA
Original Assignee
Southern Theater Command General Hospital of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Theater Command General Hospital of PLA filed Critical Southern Theater Command General Hospital of PLA
Priority to CN202211516354.2A priority Critical patent/CN115969832A/en
Priority to CN202110626296.8A priority patent/CN113425726B/en
Priority to CN202211516353.8A priority patent/CN115969831A/en
Priority to CN202211516351.9A priority patent/CN115969823A/en
Publication of CN113425726A publication Critical patent/CN113425726A/en
Application granted granted Critical
Publication of CN113425726B publication Critical patent/CN113425726B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the field of medicines, and discloses application of a sulfhydryl-containing compound in serving as and/or preparing a beta-lactamase inhibitor. The invention discloses that the sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol and 1, 4-butanediol bis (thioglycolate)) or the derivative thereof has good inhibition effect on beta-lactamase (metallo beta-lactamase and/or serine beta-lactamase), can protect antibiotics from being degraded by bacteria, improve the sensitivity of the bacteria to the antibiotics and reverse the drug resistance of the bacteria to the antibiotics for the first time; meanwhile, the sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol) and/or the derivative thereof has good synergistic effect when being combined with antibiotics, and can be used as a compound medicament for inhibiting bacteria.

Description

Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of a sulfhydryl-containing compound in serving as and/or preparing a beta-lactamase inhibitor.
Background
Beta-lactam antibiotics are the most important and commonly used antibiotics for the treatment of gram-negative bacterial infections, but the increasing resistance of bacteria to them has raised concerns in humans in recent years. Carbapenems, one of the β -lactam antibiotics, are considered to be the last line of defense against bacterial infections in humans, and with the advent of carbapenemases, humans gradually lost this most important counter.
The most significant cause of bacterial resistance to beta-lactam antibiotics is the production of beta-lactamase enzymes, which can inactivate the antibiotic activity by hydrolyzing the lactam ring of the beta-lactam antibiotic. Beta-lactamases can be classified into four classes (classes A, B, C, D) based on DNA sequence similarity, wherein the enzymes of classes A, C and D are serine-beta-lactamases (SBLs), the enzymes of class B are metallo-beta-lactamases (MBLs), and the active site contains one or two zinc ions. Metallo-beta-lactamases mainly include Imipenemase (IMPs), Verona integrant-encoded metallo-beta-lactamases (VIMs) and New Delhi metallo-beta-lactamases (NDMs). Among them, NDM-1 positive bacteria have been widely spread since the first detection in the early century.
Disclosure of Invention
The object of the first aspect of the present invention is to provide a thiol-group-containing compound or a derivative thereof for use as and/or for preparing a beta-lactamase inhibitor.
The object of the second aspect of the present invention is to provide the use of a thiol-group-containing compound or a derivative thereof as and/or for the manufacture of a medicament for increasing the sensitivity of bacteria to antibiotics.
The third aspect of the present invention is to provide the use of antibiotics and sulfhydryl-containing compounds and/or derivatives thereof in the preparation of medicaments for inhibiting bacteria.
The fourth aspect of the present invention is to provide a combination drug comprising an antibiotic and a thiol-group-containing compound and/or a derivative thereof.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in a first aspect of the invention, there is provided the use of a thiol-group-containing compound or a derivative thereof as and/or in the preparation of an inhibitor of beta-lactamase.
Preferably, the mercapto-containing compound is at least one of 1, 4-butanediol bis (mercaptoacetate), 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol, and 3-thio-1-hexanol; further at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol and 1, 4-butanediol bis (mercaptoacetate); further, 1, 4-butanediol bis (mercaptoacetate).
2-pyrazinylethylthiol having the formula C6H8N2S, the CAS number is 35250-53-4, and the structural formula is shown as the formula (I).
Figure BDA0003101274780000021
The molecular formula of the 2-methyl-3-tetrahydrofuran thiol is C5H10OS, CAS number 57124-87-5, the structural formula is shown as formula (II).
Figure BDA0003101274780000022
The molecular formula of the 3-sulfenyl-1-hexanol is C7H16OS, CAS number 51755-83-0, the constitutional formula is shown as formula (III).
Figure BDA0003101274780000023
The molecular formula of the 1, 4-butanediol bis (mercaptoacetate) is C8H14O4S2The CAS number is 10193-95-0, and the structural formula is shown as the formula (IV).
Figure BDA0003101274780000031
Preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
Preferably, the beta-lactamase is at least one of a serine beta-lactamase and a metallo beta-lactamase; further preferably, the beta-lactamase is a metallo beta-lactamase.
Preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase, an NDM-1 type metallo-beta-lactamase and a VIM-2 type metallo-beta-lactamase; further preferably, the metallo-beta-lactamase is an NDM-type 1 metallo-beta-lactamase.
Preferably, the serine beta-lactamase is a KPC-2 type serine beta-lactamase.
Preferably, the source of the beta-lactamase comprises extraction in nature or preparation from a genetically engineered strain.
In a second aspect of the invention, there is provided the use of a thiol-group-containing compound or a derivative thereof as and/or in the manufacture of a medicament for increasing the sensitivity of a bacterium to an antibiotic.
Preferably, the mercapto compound is at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate); further at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol and 3-thio-1-hexanol; further, at least one of 2-pyrazinylethylthiol and 2-methyl-3-tetrahydrofuranthiol is used.
2-pyrazinylethylthiol having the formula C6H8N2S, the CAS number is 35250-53-4, and the structural formula is shown as the formula (I).
The molecular formula of the 2-methyl-3-tetrahydrofuran thiol is C5H10OS, CAS number 57124-87-5, the structural formula is shown as formula (II).
The molecular formula of the 3-sulfenyl-1-hexanol is C7H16OS, CAS number 51755-83-0, the constitutional formula is shown as formula (III).
The molecular formula of the 1, 4-butanediol bis (mercaptoacetate) is C8H14O4S2The CAS number is 10193-95-0, and the structural formula is shown as the formula (IV).
Preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
Preferably, the bacterium is a drug-resistant bacterium that expresses a metallo beta-lactamase and/or a serine beta-lactamase; further preferably, the bacterium is at least one of Escherichia coli (Escherichia coli), Klebsiella pneumoniae (Klebsiella pneumoniae), and Pseudomonas aeruginosa (Pseudomonas aeruginosa).
Preferably, the antibiotic is a β -lactam antibiotic; further preferably, the antibiotic is at least one of penicillin antibiotics, cephalosporin antibiotics, cephamycins antibiotics, thiomycins antibiotics and carbapenems antibiotics; still further preferably, the antibiotic is at least one of meropenem, imipenem, ertapenem, cephalexin, cefuroxime, cefdinir, ceftriaxone, ceftazidime, ampicillin and amoxicillin.
Preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase, an NDM-1 type metallo-beta-lactamase and a VIM-2 type metallo-beta-lactamase; further preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase and an NDM-1 type metallo-beta-lactamase; still further preferably, the metallo-beta-lactamase is an NDM-type 1 metallo-beta-lactamase.
Preferably, the serine beta-lactamase is a KPC-2 type serine beta-lactamase.
In a third aspect of the invention, there is provided the use of an antibiotic and a thiol-group containing compound and/or a derivative thereof in the manufacture of a medicament for inhibiting bacteria.
Preferably, the mercapto compound is at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate); further at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol and 3-thio-1-hexanol; further, at least one of 2-methyl-3-tetrahydrofurothiol and 3-thio-1-hexanol is used.
2-pyrazinylethylthiol having the formula C6H8N2S, the CAS number is 35250-53-4, and the structural formula is shown as the formula (I).
The molecular formula of the 2-methyl-3-tetrahydrofuran thiol is C5H10OS, CAS number 57124-87-5, the structural formula is shown as formula (II).
The molecular formula of the 3-sulfenyl-1-hexanol is C7H16OS, CAS number 51755-83-0, the constitutional formula is shown as formula (III).
The molecular formula of the 1, 4-butanediol bis (mercaptoacetate) is C8H14O4S2The CAS number is 10193-95-0, and the structural formula is shown as the formula (IV).
Preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
Preferably, the antibiotic is a β -lactam antibiotic; further preferably, the antibiotic is at least one of penicillin antibiotics, cephalosporin antibiotics, cephamycins antibiotics, thiomycins antibiotics and carbapenems antibiotics; still further preferably, the antibiotic is at least one of meropenem, imipenem, ertapenem, cephalexin, cefuroxime, cefdinir, ceftriaxone, ceftazidime, ampicillin and amoxicillin.
Preferably, the bacterium is a drug-resistant bacterium that expresses a metallo beta-lactamase and/or a serine beta-lactamase; further preferably, the bacterium is at least one of Escherichia coli (Escherichia coli), Klebsiella pneumoniae (Klebsiella pneumoniae), and Pseudomonas aeruginosa (Pseudomonas aeruginosa).
Preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase, an NDM-1 type metallo-beta-lactamase and a VIM-2 type metallo-beta-lactamase; further preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase and an NDM-1 type metallo-beta-lactamase; still further preferably, the metallo-beta-lactamase is an NDM-type 1 metallo-beta-lactamase.
Preferably, the serine beta-lactamase is a KPC-2 type serine beta-lactamase.
In a fourth aspect of the invention, there is provided a medicament comprising:
(1) (ii) an antibiotic; and
(2) a mercapto compound and/or a derivative thereof.
Preferably, the mercapto compound is at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate); further at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol and 3-thio-1-hexanol; further, at least one of 2-pyrazinylethylthiol and 2-methyl-3-tetrahydrofuranthiol is used.
2-pyrazinylethylthiol having the formula C6H8N2S, the CAS number is 35250-53-4, and the structural formula is shown as the formula (I).
The molecular formula of the 2-methyl-3-tetrahydrofuran thiol is C5H10OS, CAS number 57124-87-5, the structural formula is shown as formula (II).
The molecular formula of the 3-sulfenyl-1-hexanol is C7H16OS, CAS number 51755-83-0, the constitutional formula is shown as formula (III).
The molecular formula of the 1, 4-butanediol bis (mercaptoacetate) is C8H14O4S2The CAS number is 10193-95-0, and the structural formula is shown as the formula (IV).
Preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
Preferably, the antibiotic is a β -lactam antibiotic; further preferably, the antibiotic is at least one of penicillin antibiotics, cephalosporin antibiotics, cephamycins antibiotics, thiomycins antibiotics and carbapenems antibiotics; still further preferably, the antibiotic is at least one of meropenem, imipenem, ertapenem, cephalexin, cefuroxime, cefdinir, ceftriaxone, ceftazidime, ampicillin and amoxicillin.
Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
Preferably, the adjuvant comprises at least one of diluent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, surfactant, adsorption carrier, and lubricant.
Preferably, the formulation types of the drug include solid formulations, liquid formulations, and semi-solid formulations.
Preferably, the solid formulation includes tablets, granules, powders and capsules.
Preferably, the liquid formulation comprises an injection.
Preferably, the semi-solid formulation comprises an ointment and a cream.
The invention has the beneficial effects that:
the invention discloses the application of sulfhydryl-containing compounds (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (thioglycolate)) or derivatives thereof in serving as and/or preparing a metallo-beta-lactamase inhibitor for the first time, wherein the sulfhydryl-containing compounds (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (thioglycolate)) or derivatives thereof have good inhibitory effect on beta-lactamase (metallo-beta-lactamase and/or serine beta-lactamase), can protect antibiotics from being degraded by bacteria, improve the sensitivity of bacteria to the antibiotics, reversing the resistance of bacteria to antibiotics; meanwhile, the sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol) and/or the derivative thereof has good synergistic effect when being combined with antibiotics, and can be used as a compound medicament for inhibiting bacteria.
Detailed Description
The present invention will be described in further detail with reference to specific examples.
It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. The materials, reagents and the like used in the present examples are commercially available reagents and materials unless otherwise specified.
EXAMPLE 1 measurement of inhibitory Activity of thiol-group-containing Compound on beta-lactamase
The substrate is hydrolyzed by the enzyme to cause the decrease of the absorbance value, so that the degree of hydrolysis of the substrate can be characterized by the change of the absorbance, thereby judging the activity of the enzyme. The change in absorbance of the substrate after hydrolysis by metallo-beta-lactamase was measured at a wavelength of 300nm using meropenem (50. mu.M) as a reporter substrate. The metallo-beta-lactamase comprises NDM-1, VIM-2 and IMP-7 with final concentration of 2nM, 4nM and 5nM respectively,the buffer was 50mM HEPES (4-hydroxyethylpiperazineethanesulfonic acid), and ZnSO was added4(final concentration 0.1mM), triton X-100 (final concentration 0.01% (v/v)), bovine serum albumin (BSA, final concentration 0.1 μ g/mL), pH 7.2, reaction temperature 25 ℃, specific experimental method as follows:
1. determination of inhibitory Activity of thiol-containing Compound on IMP-7 type metallo beta-lactamase
(1) 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate) (control with captopril, available from Shanghai leaf Biotech Co., Ltd., batch No. S30916) were dissolved in HEPES buffer and formulated to various concentrations (0.1, 0.5, 1, 5, 10, 50, 100, 300, 500. mu.M, respectively), setting three multiple wells for each concentration, adding 10 μ L IMP-7 type metallo-beta-lactamase solution (final concentration is 5nM), incubating at 25 deg.C for 15min, 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 2, 3-thio-1-hexanol, 1, 4-butanediol bis (mercaptoacetate) and captopril were allowed to bind well to the enzyme.
(2) The system is transferred into a quartz cuvette, 50 mu L of meropenem (the final concentration is 50 mu M) is added, the change of the absorbance value is rapidly measured, and the data is recorded.
(3) Calculating the inhibition rate of different concentrations of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol, 1, 4-butanediol bis (mercaptoacetate) and captopril on IMP-7 type metallo-beta-lactamase, plotting the concentration of the compound on the residual activity of IMP-7 type metallo-beta-lactamase, and calculating IC by fitting a curve50Value, and Ki ═ IC50/(1+[S]Km) (wherein, [ S ]]Km is the mie constant of the enzyme) to obtain Ki values.
2. Determination of inhibitory Activity of thiol-containing Compound on NDM-1 type metallo beta-lactamase
(1) 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate) (control with captopril, available from Shanghai leaf Biotech Co., Ltd., batch No. S30916) were dissolved in HEPES buffer and formulated to various concentrations (0.1, 0.5, 1, 5, 10, 50, 100, 300, 500. mu.M, respectively), setting three wells for each concentration, adding 10 μ L NDM-1 type metallo-beta-lactamase solution (final concentration is 2nM), incubating at 25 deg.C for 15min, 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 2, 3-thio-1-hexanol, 1, 4-butanediol bis (mercaptoacetate) and captopril were allowed to bind well to the enzyme.
(2) The system is transferred into a quartz cuvette, 50 mu L of meropenem (the final concentration is 50 mu M) is added, the change of the absorbance value is rapidly measured, and the data is recorded.
(3) Calculating the inhibition rate of different concentrations of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol, 1, 4-butanediol bis (mercaptoacetate) and captopril on NDM-1 type metallo-beta-lactamase, plotting the concentration of the compound on the residual activity of NDM-1 type metallo-beta-lactamase, and calculating IC by fitting a curve50The value is calculated, and the Ki value is obtained.
3. Determination of inhibitory Activity of thiol-containing Compound on VIM-2 type metallo beta-lactamase
(1) 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate) (control with captopril, available from Shanghai leaf Biotech Co., Ltd., batch No. S30916) were dissolved in HEPES buffer and formulated to various concentrations (0.1, 0.5, 1, 5, 10, 50, 100, 300, 500. mu.M, respectively), setting three wells for each concentration, adding 10 μ L VIM-2 type metallo-beta-lactamase solution (final concentration is 4nM), incubating at 25 deg.C for 15min, 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate) (captopril) were allowed to bind well to the enzyme.
(2) The system is transferred into a quartz cuvette, 50 mu L of meropenem (the final concentration is 50 mu M) is added, the change of the absorbance value is rapidly measured, and the data is recorded.
(3) Calculating the inhibition rate of different concentrations of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuryl mercaptan, 3-thio-1-hexanol, 1, 4-butanediol bis (mercaptoacetate) and captopril on VIM-2 type metallo-beta-lactamase, and determining the concentration of the compound to the residual rate of the VIM-2 type metallo-beta-lactamaseViability mapping, IC calculated by fitting curves50The value is calculated, and the Ki value is obtained.
The results of the inhibitory activity of the mercapto compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate)) and captopril against metallic beta-lactamases of IMP-7 type, NDM-1 type and VIM-2 type are shown in Table 1: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranyl thiol and 1, 4-butanediol bis (thioglycolate) have an inhibitory effect on NDM-1 type metallo beta-lactamase, 2-pyrazinylethylthiol and 2-methyl-3-tetrahydrofuranyl thiol have an inhibitory effect on VIM-2 type metallo beta-lactamase, 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranyl thiol and 3-thio-1-hexanol have a good inhibitory effect on IMP-7 type metallo beta-lactamase, and particularly 1, 4-butanediol bis (thioglycolate) has an inhibitory effect on NDM-1 type metallo beta-lactamase better than that of captopril.
TABLE 1 sulfhydryl-containing Compounds and IC's of captopril against metallic beta-lactamases of IMP-7 type, NDM-1 type and VIM-2 type50(. mu.M) and Ki (. mu.M)
Figure BDA0003101274780000081
Example 2 evaluation of Effect of Using a mercapto Compound in combination with Meropenem in inhibiting production of beta-lactamase-resistant bacteria
The Minimum Inhibitory Concentration (MIC) of the combination of the sulfhydryl-containing compound and meropenem on beta-lactamase-resistant strains is determined by adopting a trace broth dilution method. The experimental E.coli BL21(DE3)/pMAL-c5x-IMP-7 was purchased from Shanghai Biotech Co., Ltd, and E.coli BL21(DE3)/pET24a-VIM-2 and E.coli BL21(DE3)/pET26b-NDM-1 were obtained from the professor David university of the North West David of the department of Populaceae, and were described in the literature: characterization and inhibition studies of Zhang-Yuan, antibiotic-resistant target protein metallo-beta-lactamase and drug-resistant bacteria thereof [ D]Northwest university, 2019; also included is the clinical isolate E.coli BAA-2452 (bla) purchased from Beijing Baiohobowei Biotechnology CoNDM-1) Coli BAA-2340 (bla)KPC-2)。
FICI is used to judge the interaction of two drugs when used in combination and is defined according to the following equationA+FICB＝CA/MICA+CB/MICBWherein MICAAnd MICBMIC values for Compounds A and B, respectively, alone, and CAAnd CBIs the drug concentration of compound a and B in the effective combination. If the FICI is less than or equal to 0.5, the two medicines are considered to have synergistic action, if the FICI is more than 0.5 and less than or equal to 4, the two medicines are considered to have weak synergistic action or no related action, and if the FICI is more than or equal to 4, the two medicines are considered to have antagonistic action. The smaller the FICI, the stronger the drug synergy.
The specific experimental method is as follows:
1. evaluation of Effect of combination of thiol-containing Compound and meropenem in inhibiting production of IMP-7 type drug-resistant bacteria
(1) Inoculating strain (E.coli BL21(DE3)/pMAL-c5 x-IMP-7) in sterile LB solid culture medium under aseptic condition, culturing at 37 deg.C overnight, selecting single colony, transferring to 3mL LB liquid culture medium (containing 50mg/mL ampicillin), culturing at 37 deg.C to logarithmic phase to obtain bacterial suspension, adjusting bacterial concentration to 0.5 Mr.m.concentration with Mr.m. turbidimeter, diluting LB liquid culture medium by 100 times, and counting about 1 × 106CFU/mL。
(2) Adding 100 mu L of LB liquid culture medium into the 2 nd to 12 th rows of a 96-well plate, adding 100 mu L of meropenem solution (256 mu g/mL) or an inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate), 256 mu g/mL) into the 1 st row, sucking 100 mu L of the 2 nd row liquid medicine after fully mixing the liquid medicine, adding the liquid medicine into the 3 rd row, mixing the liquid medicine again, and sequentially diluting the liquid medicine by a double-proportion dilution method to obtain the medicine concentration of 0.0625 to 128 mu g/mL; the MIC of Meropenem or a mercapto compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate)) alone against IMP-7 type drug-resistant bacteria was determined by adding 100. mu.L of diluted bacterial solution to each well, and three wells were set at each concentration.
(3) Jointly diluting the liquid medicine on a 96-well plate in the horizontal and vertical directions, and performing gradient dilution of meropenem in the horizontal row, wherein the method is the same as the step (2), but the volumes of the added LB liquid culture medium and the meropenem are both 50 mu L (the final concentration of the meropenem is 0.0625-128 mu g/mL), and 50 mu L of inhibitors (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-sulfenyl-1-hexanol or 1, 4-butanediol bis (thioglycolate)) with different concentrations, which are diluted in a double proportion in advance, are added in the vertical row, and the final concentration is 2-128 mu g/mL; each well was filled with 100. mu.L of diluted bacterial solution, and MIC of meropenem in combination with an inhibitor (a mercapto compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) against IMP-7-type drug-resistant bacteria was determined, three wells per concentration.
(4) Each set of experiments was set up with three parallel controls: taking Escherichia coli ATCC25922 as a quality control standard, taking captopril as a positive control, and simultaneously arranging a sterile hole and a drug-free hole; the 96-well plate was incubated in a 37 ℃ incubator for 24 hours, and the results were observed and MIC values were recorded.
2. Evaluation of effect of combination of sulfhydryl-containing compound and meropenem on inhibiting generation of VIM-2 type drug-resistant bacteria
(1) Inoculating a strain (E.coli BL21(DE3)/pET24a-VIM-2 strain) preserved at ultralow temperature into a sterile LB solid culture medium under the aseptic operating condition, placing the strain in a constant temperature incubator at 37 ℃ for overnight culture, picking a single colony, transferring the single colony into 3mL of LB liquid culture medium (containing 50mg/mL of kanamycin), and culturing the single colony in the constant temperature incubator at 37 ℃ until the logarithmic growth phase to obtain a bacterial suspension; adjusting the concentration of the bacterial liquid to 0.5 McLeod concentration by a McLeod turbidimeter, diluting the LB liquid culture medium by 100 times, and obtaining the bacterial number of about 1 × 106CFU/mL。
(2) Adding 100 mu L of LB liquid culture medium into the 2 nd to 12 th rows of a 96-well plate, adding 100 mu L of meropenem solution (256 mu g/mL) or an inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate), 256 mu g/mL) into the 1 st row, sucking 100 mu L of the 2 nd row liquid medicine after fully mixing the liquid medicine, adding the liquid medicine into the 3 rd row, mixing the liquid medicine again, and sequentially diluting the liquid medicine by a double-proportion dilution method to obtain the medicine concentration of 0.0625 to 128 mu g/mL; the MIC of Meropenem or a thiol-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate)) alone against drug-resistant bacteria of type VIM-2 was determined by adding 100. mu.L of diluted bacterial solution to each well, and three wells were provided for each concentration.
(3) Jointly diluting the liquid medicine on a 96-well plate in the horizontal and vertical directions, and performing gradient dilution of meropenem in the horizontal row, wherein the method is the same as the step (2), but the volumes of the added LB liquid culture medium and the meropenem are both 50 mu L (the final concentration of the meropenem is 0.0625-128 mu g/mL), and 50 mu L of inhibitors (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-sulfenyl-1-hexanol or 1, 4-butanediol bis (thioglycolate)) with different concentrations, which are diluted in a double proportion in advance, are added in the vertical row, and the final concentration is 2-128 mu g/mL; each well was filled with 100. mu.L of diluted bacterial solution, and MIC of meropenem in combination with an inhibitor (a mercapto compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) against drug-resistant bacteria of type VIM-2 was determined, three wells per concentration.
(4) Each set of experiments was set up with three parallel controls: taking Escherichia coli ATCC25922 as a quality control standard, taking captopril as a positive control, and simultaneously arranging a sterile hole and a drug-free hole; the 96-well plate was incubated in a 37 ℃ incubator for 24 hours, and the results were observed and MIC values were recorded.
3. Evaluation of Effect of combination of thiol-containing Compound and Meropenem in inhibiting production of NDM-1 type drug-resistant bacteria
(1) Inoculating a strain (E.coli BL21(DE3)/pET26b-NDM-1 strain) preserved at ultralow temperature into a sterile LB solid culture medium under the aseptic operating condition, placing the strain in a constant temperature incubator at 37 ℃ for overnight culture, picking a single colony, transferring the single colony into 3mL of LB liquid culture medium (containing 50mg/mL of kanamycin), and culturing the single colony in the constant temperature incubator at 37 ℃ until the logarithmic growth phase to obtain a bacterial suspension; adjusting the concentration of the bacterial liquid to 0.5 McLeod concentration by a McLeod turbidimeter, diluting the LB liquid culture medium by 100 times, and obtaining the bacterial number of about 1 × 106CFU/mL。
(2) Adding 100 mu L of LB liquid culture medium into the 2 nd to 12 th rows of a 96-well plate, adding 100 mu L of meropenem solution (256 mu g/mL) or an inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate), 256 mu g/mL) into the 1 st row, sucking 100 mu L of the 2 nd row liquid medicine after fully mixing the liquid medicine, adding the liquid medicine into the 3 rd row, mixing the liquid medicine again, and sequentially diluting the liquid medicine by a double-proportion dilution method to obtain the medicine concentration of 0.0625 to 128 mu g/mL; the MIC of Meropenem or a mercapto compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) alone against NDM-1 type drug-resistant bacteria was determined by adding 100. mu.L of diluted bacterial solution to each well, and three wells were set at each concentration.
(3) Jointly diluting the liquid medicine on a 96-well plate in the horizontal and vertical directions, and performing gradient dilution of meropenem in the horizontal row, wherein the method is the same as the step (2), but the volumes of the added LB liquid culture medium and the meropenem are both 50 mu L (the final concentration of the meropenem is 0.0625-128 mu g/mL), and 50 mu L of inhibitors (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-sulfenyl-1-hexanol or 1, 4-butanediol bis (thioglycolate)) with different concentrations, which are diluted in a double proportion in advance, are added in the vertical row, and the final concentration is 2-128 mu g/mL; each well was filled with 100. mu.L of diluted bacterial solution, and MIC of Meropenem in combination with an inhibitor (mercapto compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) against NDM-1 type drug-resistant bacteria was determined, three wells per concentration.
(4) Each set of experiments was set up with three parallel controls: taking Escherichia coli ATCC25922 as a quality control standard, taking captopril as a positive control, and simultaneously arranging a sterile hole and a drug-free hole; the 96-well plate was incubated in a 37 ℃ incubator for 24 hours, and the results were observed and MIC values were recorded.
4. Clinical isolate e.coli BAA-2452 (bla) was inhibited by combination of thiol-containing compound and meropenemNDM-1) Evaluation of Effect
(1) A strain (clinical isolate E.coli BAA-2452 (bla) was stored at ultra-low temperature under aseptic conditionsNDM-1) Inoculating in sterile LB solid medium, culturing overnight in 37 deg.C incubator, and selecting single colonyTransferring the strain to 3mL of LB liquid culture medium, and culturing the strain in a constant temperature incubator at 37 ℃ until the strain reaches logarithmic growth phase to obtain bacterial suspension; adjusting the concentration of the bacterial liquid to 0.5 McLeod concentration by a McLeod turbidimeter, diluting the LB liquid culture medium by 100 times, and obtaining the bacterial number of about 1 × 106CFU/mL。
(2) Adding 100 mu L of LB liquid culture medium into the 2 nd to 12 th rows of a 96-well plate, adding 100 mu L of meropenem solution (256 mu g/mL) or an inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate), 256 mu g/mL) into the 1 st row, sucking 100 mu L of the 2 nd row liquid medicine after fully mixing the liquid medicine, adding the liquid medicine into the 3 rd row, mixing the liquid medicine again, and sequentially diluting the liquid medicine by a double-proportion dilution method to obtain the medicine concentration of 0.0625 to 128 mu g/mL; clinical isolates E.coli BAA-2452 (bla) were assayed by adding 100. mu.L of diluted bacterial suspension to each well and using meropenem or a thiol-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate)) aloneNDM-1) Three replicate wells per concentration.
(3) Diluting the liquid medicine on a 96-well plate in a horizontal direction and a vertical direction in a combined manner, and performing gradient dilution of meropenem in the horizontal row in the same step (2), wherein the volumes of the added LB liquid culture medium and the meropenem are both 50 mu L (the final concentration of meropenem is 0.0625-128 mu g/mL), 50 mu L of inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuran thiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate) with different concentrations, which are diluted in a double-fold manner in advance, is added in the vertical row, the final concentration is 2-128 mu g/mL, 100 mu L of diluted bacterial liquid is added in each well, and the meropenem and the inhibitor (the sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuran thiol) are determined by using the method, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) in combination with clinical isolate ENDM-1) Three replicate wells per concentration.
(4) Each set of experiments was set up with three parallel controls: taking Escherichia coli ATCC25922 as a quality control standard, taking captopril as a positive control, and simultaneously arranging a sterile hole and a drug-free hole; the 96-well plate was incubated in a 37 ℃ incubator for 24 hours, and the results were observed and MIC values were recorded.
5. Clinical isolate e.coli BAA-2340 (bla) was inhibited by the combination of thiol-containing compounds with meropenemKPC-2) Evaluation of Effect
(1) The strain that was stored at ultra-low temperature (clinical isolate E. coli BAA-2340 (bla) was used under aseptic conditionsKPC-2) Inoculating into a sterile LB solid culture medium, placing in a constant temperature incubator at 37 ℃ for overnight culture, selecting a single colony, transferring into 3mL of LB liquid culture medium, and culturing in the constant temperature incubator at 37 ℃ until the logarithmic phase to obtain a bacterial suspension; adjusting the concentration of the bacterial liquid to 0.5 McLeod concentration by a McLeod turbidimeter, diluting the LB liquid culture medium by 100 times, and obtaining the bacterial number of about 1 × 106CFU/mL。
(2) Adding 100 mu L of LB liquid culture medium into the 2 nd to 12 th rows of a 96-well plate, adding 100 mu L of meropenem solution (256 mu g/mL) or an inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate), 256 mu g/mL) into the 1 st row, sucking 100 mu L of the 2 nd row liquid medicine after fully mixing the liquid medicine, adding the liquid medicine into the 3 rd row, mixing the liquid medicine again, and sequentially diluting the liquid medicine by a double-proportion dilution method to obtain the medicine concentration of 0.0625 to 128 mu g/mL; clinical isolates E.coli BAA-2340 (bla) were assayed by adding 100. mu.L of diluted bacterial suspension to each well and using meropenem or a thiol-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate)) aloneKPC-2) Three replicate wells per concentration.
(3) Diluting the liquid medicine on a 96-well plate in a horizontal direction and a vertical direction in a combined manner, and performing gradient dilution of meropenem in the horizontal row in the same step (2), wherein the volumes of the added LB liquid culture medium and the meropenem are both 50 mu L (the final concentration of the meropenem is 0.0625-128 mu g/mL), 50 mu L of inhibitor (a sulfhydryl-containing compound: 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranethiol, 3-thio-1-hexanol or 1, 4-butanediol bis (thioglycolate)) with different concentrations, which are diluted in a double ratio in advance, is added in the vertical row, the final concentration is 2-128 mu g/mL, 100 mu L of diluted bacterial liquid is added in each well, and the meropenem and the inhibitor (the sulfhydryl-containing compound: 2-pyrazinylethylethanethiol) are determined by using the methodClinical isolate E.coli BAA-2340 (bla) in combination with thiol, 2-methyl-3-tetrahydrofuranethiol, 3-thio-1-hexanol or 1, 4-butanediol bis (mercaptoacetate))KPC-2) Three replicate wells per concentration.
(4) Each set of experiments was set up with three parallel controls: taking Escherichia coli ATCC25922 as a quality control standard, taking captopril as a positive control, and simultaneously arranging a sterile hole and a drug-free hole; the 96-well plate was incubated in a 37 ℃ incubator for 24 hours, and the results were observed and MIC values were recorded.
The results of the antibacterial activity of meropenem in combination with a mercapto-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate)) against drug-resistant bacteria expressing NDM-1, VIM-2, IMP-7 or KPC-2 are shown in Table 2: inhibitors (thiol-containing compounds (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol, 1, 4-butanediol bis (thioglycolate)), captopril) can enhance the antibacterial activity of meropenem: when the concentration of the inhibitor is 128 mug/mL, the inhibitor is used together with meropenem, the bacteriostatic effect of the meropenem on various drug-resistant bacteria expressing beta-lactamase can be improved, and compared with the single use of the meropenem, the combined use can effectively reduce the MIC value of the meropenem on drug-resistant strains, and can be reduced by 8 times at most.
FICI values for the combination of thiol-containing compounds (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (thioglycolate)) or captopril with meropenem against drug-resistant bacteria expressing beta-lactamase are shown in Table 3: the FICI value of the combination of the sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-sulfenyl-1-hexanol) and meropenem on drug-resistant bacteria expressing NDM-1 type metallo-beta-lactamase is less than or equal to 0.5, which shows that the sulfhydryl-containing compound and the meropenem have good synergistic effect; the FICI value of the combination of 2-pyrazinylethylthiol and meropenem on drug-resistant bacteria expressing IMP-7 type metallo beta-lactamase is less than or equal to 0.5, which shows that the two have good synergistic effect; the FICI value of the combination of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol and meropenem on drug-resistant bacteria expressing KPC-2 type serine beta-lactamase is less than or equal to 0.5, which shows that the combination has good synergistic effect, and the FICI value of the combination of captopril and meropenem on drug-resistant bacteria expressing KPC-2 type serine beta-lactamase is more than 1, which shows that the combination does not have synergistic effect.
The above results show that: when the composition is used with meropenem, the sulfhydryl-containing compounds (2-pyrazinylethanethiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol) have effective synergistic antibacterial activity on drug-resistant bacteria expressing NDM-1 type metallo-beta-lactamase, the 2-pyrazinylethanethiol has effective synergistic antibacterial activity on drug-resistant bacteria expressing IMP-7 type metallo-beta-lactamase, and the sulfhydryl-containing compounds (2-pyrazinylethanethiol, 2-methyl-3-tetrahydrofuranthiol) have effective synergistic antibacterial activity on drug-resistant bacteria expressing KPC-2 type serine beta-lactamase, which shows that the sulfhydryl-containing compounds (2-pyrazinylethanethiol, 2-methyl-3-tetrahydrofuranthiol, etc.), 3-sulfenyl-1-hexanol) can be used as an NDM-1 type metallo beta-lactamase inhibitor, 2-pyrazinylethylthiol can be used as an IMP-7 type metallo beta-lactamase inhibitor, and a sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurylthiol) can be used as a KPC-2 type serine beta-lactamase inhibitor, so that the drug resistance of carbapenem resistant bacteria can be reversed, meropenem is effectively protected from being hydrolyzed by NDM-1 type, IMP-7 type and KPC-2 type metallo beta-lactamase, and the antibacterial activity of the meropenem on drug-resistant bacteria producing NDM-1 type, IMP-7 type and KPC-2 type metallo beta-lactamase is improved. Therefore, the sulfhydryl-containing compound (2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-sulfenyl-1-hexanol) can be used as a beta-lactamase inhibitor to be prepared into a compound preparation with beta-lactam antibiotics.
TABLE 2 MIC (μ g/mL) of thiol-containing Compounds or Captopril in combination with Meropenem for drug-resistant bacteria expressing β -lactamase
Figure BDA0003101274780000131
Figure BDA0003101274780000141
TABLE 3 synergistic antimicrobial index (FICI) of combinations of thiol-containing compounds or captopril with meropenem against beta-lactamase-expressing drug-resistant bacteria
Figure BDA0003101274780000142
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (10)

1. Use of a thiol-containing compound which is at least one of 1, 4-butanediol bis (thioglycolate), 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofurothiol and 3-thio-1-hexanol, or a derivative thereof, as an inhibitor of and/or for the preparation of a beta-lactamase.
2. Use according to claim 1, characterized in that:
the beta-lactamase is at least one of serine beta-lactamase and metallo beta-lactamase;
preferably, the metallo-beta-lactamase is at least one of an IMP-7 type metallo-beta-lactamase, an NDM-1 type metallo-beta-lactamase and a VIM-2 type metallo-beta-lactamase;
preferably, the serine beta-lactamase is a KPC-2 type serine beta-lactamase;
preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
3. Use of a thiol-containing compound which is at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranethiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate), or a derivative thereof, as and/or in the manufacture of a medicament for increasing the sensitivity of bacteria to antibiotics.
4. Use according to claim 3, characterized in that:
the antibiotic is beta-lactam antibiotic.
5. Use according to claim 4, characterized in that:
the bacteria are drug-resistant bacteria expressing metallo-beta-lactamase and/or serine beta-lactamase;
preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
6. Use of an antibiotic and a mercapto compound and/or a derivative thereof in the manufacture of a medicament for inhibiting bacteria, the mercapto compound being at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate).
7. Use according to claim 6, characterized in that:
the antibiotic is beta-lactam antibiotic.
8. Use according to claim 7, characterized in that:
the bacteria are drug-resistant bacteria expressing metallo-beta-lactamase and/or serine beta-lactamase;
preferably, the derivative includes a pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomer or prodrug of the thiol-containing compound.
9. A medicament, comprising:
(1) (ii) an antibiotic; and
(2) a mercapto-containing compound and/or a derivative thereof;
the sulfhydryl-containing compound is at least one of 2-pyrazinylethylthiol, 2-methyl-3-tetrahydrofuranthiol, 3-thio-1-hexanol and 1, 4-butanediol bis (mercaptoacetate).
10. The medicament of claim 9, wherein:
the antibiotic is beta-lactam antibiotic.
CN202110626296.8A 2021-06-04 2021-06-04 Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor Active CN113425726B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202211516354.2A CN115969832A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitor
CN202110626296.8A CN113425726B (en) 2021-06-04 2021-06-04 Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor
CN202211516353.8A CN115969831A (en) 2021-06-04 2021-06-04 Use of bis (mercaptoacetate) derivatives as beta-lactamase inhibitors
CN202211516351.9A CN115969823A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110626296.8A CN113425726B (en) 2021-06-04 2021-06-04 Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202211516354.2A Division CN115969832A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitor
CN202211516353.8A Division CN115969831A (en) 2021-06-04 2021-06-04 Use of bis (mercaptoacetate) derivatives as beta-lactamase inhibitors
CN202211516351.9A Division CN115969823A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
CN113425726A true CN113425726A (en) 2021-09-24
CN113425726B CN113425726B (en) 2022-11-15

Family

ID=77803706

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202211516353.8A Pending CN115969831A (en) 2021-06-04 2021-06-04 Use of bis (mercaptoacetate) derivatives as beta-lactamase inhibitors
CN202211516351.9A Pending CN115969823A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitors
CN202211516354.2A Pending CN115969832A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitor
CN202110626296.8A Active CN113425726B (en) 2021-06-04 2021-06-04 Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202211516353.8A Pending CN115969831A (en) 2021-06-04 2021-06-04 Use of bis (mercaptoacetate) derivatives as beta-lactamase inhibitors
CN202211516351.9A Pending CN115969823A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitors
CN202211516354.2A Pending CN115969832A (en) 2021-06-04 2021-06-04 Beta-lactamase inhibitor

Country Status (1)

Country Link
CN (4) CN115969831A (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101060843A (en) * 2004-09-17 2007-10-24 赛宁制药公司 Quinolone analogs as cell proliferation inhibitors
WO2008011191A1 (en) * 2006-07-21 2008-01-24 Replidyne, Inc. Antibacterial heterocyclic ureas
WO2009131692A1 (en) * 2008-04-23 2009-10-29 The Board Of Trustees Of The University Of Alabama Substrates for delivery of physiologically active agents
US20150306075A1 (en) * 2014-04-23 2015-10-29 Case Western Reserve University Compositions and methods of inhibiting metallo-b-lactamases
EP2979694A1 (en) * 2014-08-01 2016-02-03 Université de Fribourg Succinic acid compounds for use in bacterial infections
EP3020415A1 (en) * 2014-11-17 2016-05-18 Université de Fribourg Thiol compounds for use in bacterial infections
CN107184581A (en) * 2017-06-02 2017-09-22 郑州大学 Application of the dithiocarbamate derivative in antibacterial field
US20170369433A1 (en) * 2014-10-03 2017-12-28 Oxford University Innovation Limited Beta Lactamase Inhibitors
CN108272800A (en) * 2018-02-14 2018-07-13 西北大学 Pyridine -2,6- dioctyl phthalate is preparing the application in inhibiting drug-resistant bacteria active medicine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101060843A (en) * 2004-09-17 2007-10-24 赛宁制药公司 Quinolone analogs as cell proliferation inhibitors
WO2008011191A1 (en) * 2006-07-21 2008-01-24 Replidyne, Inc. Antibacterial heterocyclic ureas
WO2009131692A1 (en) * 2008-04-23 2009-10-29 The Board Of Trustees Of The University Of Alabama Substrates for delivery of physiologically active agents
US20150306075A1 (en) * 2014-04-23 2015-10-29 Case Western Reserve University Compositions and methods of inhibiting metallo-b-lactamases
EP2979694A1 (en) * 2014-08-01 2016-02-03 Université de Fribourg Succinic acid compounds for use in bacterial infections
US20170369433A1 (en) * 2014-10-03 2017-12-28 Oxford University Innovation Limited Beta Lactamase Inhibitors
EP3020415A1 (en) * 2014-11-17 2016-05-18 Université de Fribourg Thiol compounds for use in bacterial infections
CN107184581A (en) * 2017-06-02 2017-09-22 郑州大学 Application of the dithiocarbamate derivative in antibacterial field
CN108272800A (en) * 2018-02-14 2018-07-13 西北大学 Pyridine -2,6- dioctyl phthalate is preparing the application in inhibiting drug-resistant bacteria active medicine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YU-HANG YAN ET AL: ""Discovery of Mercaptopropanamide-substituted Aryl Tetrazoles as New Broad-Spectrum Metallo-β-lactamase Inhibitors"", 《RSC ADV.》 *
YU-HANG YAN ET AL: ""Principles and current strategies targeting metallo‐β‐lactamase mediated antibacterial resistance"", 《MEDICINAL RESEARCH REVIEWS》 *

Also Published As

Publication number Publication date
CN113425726B (en) 2022-11-15
CN115969823A (en) 2023-04-18
CN115969831A (en) 2023-04-18
CN115969832A (en) 2023-04-18

Similar Documents

Publication Publication Date Title
Neu et al. Comparative activity and β-lactamase stability of cefoperazone, a piperazine cephalosporin
Neu et al. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin
Fu et al. Azlocillin and mezlocillin: new ureido penicillins
Hunter et al. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin
Shannon et al. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases
Fu et al. Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin
Aswapokee et al. A sulfone β-lactam compound which acts as a β-lactamase inhibitor
Neu et al. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin
Trager et al. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity
Hata et al. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum
Neu et al. The activity of BMY 28142 a new broad spectrum β-lactamase stable cephalosporin
Hanslo et al. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics
Chin et al. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746
Dalhoff et al. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria
CN113209090B (en) Application of methimazole in preparation of metallo-beta-lactamase inhibitor
CN113425726B (en) Application of sulfhydryl-containing compound as and/or in preparation of beta-lactamase inhibitor
CN113521044B (en) Application of 2- (1- (mercaptomethyl) cyclopropyl) acetic acid as and/or in preparation of beta-lactamase inhibitor
CN112999220B (en) Application of alpha-lipoic acid as and/or preparing metallo-beta-lactamase inhibitor
Neu et al. In vitro antibacterial activity and β-lactamase stability of SCE-129, a new cephalosporin
Scriver et al. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens
CN114129564B (en) Application of epalrestat or pharmaceutically acceptable salt thereof in preparation of medicines for preventing and/or treating bacterial infection diseases
Chantot et al. Antibacterial activity of RU44790, a new N-tetrazolyl monocyclic beta-lactam
Neu et al. In vitro activity and beta-lactamase stability of a new monobactam, B0-1165
Vuye In vitro activity and β-lactamase stability of N-formimidoyl thienamycin compared to that of second and third generation cephalosporins
Counts et al. Comparative in vitro activity of the new oral cephalosporin cefixime

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant